GlassScriptPhysician profile
Bradley K Harrison
NPI 1063553188
$313,587.82
in general payments reported to CMS, 2019-2025
44 companies · $65K in 2025
The $65K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $47K · 2021: $44K · 2022: $49K · 2023: $20K · 2024: $38K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $117K · Travel and Lodging: $4,158 · Food and Beverage: $1,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116,963.94 |
| Travel and Lodging | $4,157.87 |
| Food and Beverage | $1,844.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $298,068.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $10,828.11 | 2019-2023 | Spravato |
| Lilly USA, LLC | $511.29 | 2019-2024 | Trulicity, Mounjaro, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $380.87 | 2020-2023 | Xifaxan |
| Amgen INC. | $378.24 | 2019-2023 | Prolia, Evenity, Repatha |
| Glaxosmithkline, LLC. | $330.52 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $295.49 | 2020-2024 | |
| Watermark Medical, INC. | $286.76 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $258.65 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.30 | 2019-2022 | |
| Pfizer INC. | $198.48 | 2019-2023 | |
| Gilead Sciences, INC. | $184.81 | 2019-2022 | |
| Allergan, INC. | $177.86 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $153.44 | 2019-2023 | Farxiga, Breztri |
| Teva Pharmaceuticals USA, INC. | $152.62 | 2019-2023 | Ajovy |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.